Study Reveals 80% of Lung Cancer Deaths in Brazil Linked to Smoking

Regulations by 2FIRSTS.ai
May.17.2024
Study Reveals 80% of Lung Cancer Deaths in Brazil Linked to Smoking
Study at GRELL 2024 reveals 80% of Brazil lung cancer deaths linked to smoking, causing concerns for public health.

According to a report from Brazilian media SBTNEWS on May 16th, a study presented at the Latin American Cancer Epidemiology and Registration Organization annual meeting (GRELL 2024) held by the Cancer Foundation in Switzerland revealed that 80% of male and female lung cancer deaths in Brazil are related to smoking (nicotine dependence). Alfredo Scaff, medical advisor at the Cancer Foundation, stated that the purpose of this study is to present data that can help prevent the disease to society.

 

A standard journalistic translation is: Skaf believes that there is a direct relationship between lung cancer and smoking habits, stating that "strictly speaking, smoking is currently the main cause of cancer worldwide, especially in Brazil.

 

There is controversy surrounding the use of e-cigarettes as a method to quit smoking, according to Scarf. In most cases, he believes it only leads to a habit of addiction to smoking. Scarf has warned that e-cigarettes may further increase the death rate from lung cancer caused by smoking. He also reminds people to be aware that nicotine is the most addictive substance in legal drugs.

 

A study has shown that the annual cost of lung cancer in Brazil reaches up to 9 billion Reais, including direct medical expenses, loss of productivity, and care for patients. However, the tobacco industry only covers 10% of the total expenses related to lung cancer in Brazil, amounting to 125 billion Reais.

 

Skaf pointed out that smoking not only leads to lung cancer but also to tooth decay, damage to the mouth and throat, chronic obstructive pulmonary disease, hypertension, acute myocardial infarction, and stroke. All of these contribute to increased direct costs in the public domain, such as treatment expenses, as well as indirect costs like productivity losses, budget expenditures, and so on.

 

The National Cancer Institute of Brazil predicts that this year there will be 14,000 new cases of lung cancer in women and 18,000 new cases in men. Additionally, the research found that the majority of patients, whether male (63.1%) or female (63.9%), seek medical attention when the disease has already reached an advanced stage. This is a widespread phenomenon across all regions of Brazil.

 

Researchers from the Cancer Foundation analyzed global data from the International Agency for Research on Cancer (IARC) and found that if current smoking patterns continue, the incidence and mortality rates of lung cancer are projected to increase by over 65% and 74% respectively by the year 2040 compared to 2022.

 

In the southern region, smoking is very common. The incidence of lung cancer in the southern region is higher, with 24.14 cases per 100,000 for men and 15.54 cases per 100,000 for women, exceeding the national average of 12.73 cases for men and 9.26 cases for women.

 

The incidence rates of lung cancer in men are lower than the national average in the southern and northeastern regions, while the incidence rates in women in the southern, northeastern, and southeastern regions are 8.27 cases, 8.46 cases, and 8.92 cases per 100,000 people, respectively, also lower than the national average. In all age groups, the male lung cancer mortality rate in the southern region is the highest in the country. According to research, the lung cancer mortality rate in men aged 40-59 in the southern region is 16.03 cases per 100,000 people, while for those aged 60 and above, it is 132.26 cases per 100,000 people.

 

According to information from the Brazilian news agency, Brazil is facing an even more serious issue as many patients are already in the late stages of their illness when seeking treatment. This is not only the case for male patients (63.1%), but also for female patients (63.9%). This is a trend seen across all regions of Brazil.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
At InterTabac 2026 in Dortmund, PMI is presenting multiple brands and products along “The PMI Boulevard,” including IQOS, ZYN, VEEV and Marlboro. On-site images captured by 2Firsts show dedicated spaces including the IQOS Boutique, ZYN Café, PMI Gallery and Marlboro Office
Market
Sep.16 by 2Firsts Perspectives
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Philip Morris International (PMI) has launched ZYN Melts in the UK, introducing a fully dissolvable oral nicotine tablet format alongside the brand's existing nicotine pouches. The range includes Cool Mint and Peppermint, each offered at 1mg and 2mg of nicotine per tablet, creating four SKUs. Each can contains 20 tablets and is priced at £6.50 in the UK. Unlike ZYN nicotine pouches, Melts are placed between the upper lip and gum and dissolve completely during use.
News
Sep.29 by 2Firsts Perspectives
Germany Probes 7.6 Million Illegal Vape Case With Estimated €33.3 Million Tax Loss; Four Chinese Manufacturer Employees Under Investigation, Some Packaging in Enforcement Images Resembles FUMOT Products
Germany Probes 7.6 Million Illegal Vape Case With Estimated €33.3 Million Tax Loss; Four Chinese Manufacturer Employees Under Investigation, Some Packaging in Enforcement Images Resembles FUMOT Products
German prosecutors and customs authorities are conducting a criminal investigation into an alleged cross-border organised vape network. Authorities say that between January 2024 and March 2025, four employees of an unnamed Chinese e-cigarette manufacturer allegedly built a network of sales agents and wholesalers that brought more than 7.6 million nicotine disposable vapes into Germany, causing an estimated €33.3 million in excise-tax losses. The manufacturer has not been named. Some products visible in enforcement images have packaging resembling products from FUMOT’s portfolio. European regulatory records from 2024, FUMOT’s public overseas-sales materials and records involving German vape importer and distribution company Zamu-Pro GmbH also show FUMOT/RandM products and German distribution activity during the period covered by the investigation.
Sep.21
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Malaysia’s Vape Rules Face Review as Health Minister Dzulkefly Ahmad Addresses Dropped Nicotine Appeal
Malaysia’s Vape Rules Face Review as Health Minister Dzulkefly Ahmad Addresses Dropped Nicotine Appeal
According to Free Malaysia Today on August 26, 2026, Malaysia’s Health Minister Dzulkefly Ahmad said the Health Ministry would explain the government’s decision to withdraw its appeal against a High Court ruling involving the exemption of liquid nicotine used in vape products from the Poisons List. The High Court previously ruled that the exemption decision was irrational. Dzulkefly said withdrawing the appeal did not mean the government would stop regulating vaping, and that future regulatory approaches would continue under existing legal frameworks.
Aug.28
California Lawmakers Pass Disposable Nicotine Vape Ban, With Sales Prohibition Set for 2028
California Lawmakers Pass Disposable Nicotine Vape Ban, With Sales Prohibition Set for 2028
According to CBS Los Angeles on August 27, 2026, California lawmakers have passed Assembly Bill 762, which would phase out disposable, battery-embedded nicotine vapes in the state. If signed by Governor Gavin Newsom, manufacturing and importation of the covered products would be prohibited beginning January 1, 2027, followed by a sales ban on January 1, 2028. Driven primarily by concerns over electronic waste, lithium-battery fires and environmental pollution, the legislation would further shift California’s legal vape market toward rechargeable, refillable or replaceable-pod devices.
Aug.28